SAFC Launches ADC ExpressSM to Expedite Preclinical Antibody Drug Conjugation Services
Sigma-Aldrich Corporation has announced that SAFC Commercial, its custom manufacturing services business unit, has introduced ADC Express preclinical development services within its Contract Manufacturing Services portfolio. This ADC (antibody drug conjugate) offering includes rapid preparation of development grade conjugate constructs for clients to use in their target molecule identification.
“ADC Express reflects our drive to offer our customers a full service solution to the development of their ADCs. SAFC is the reliable, experienced partner that customers can depend on as they navigate the complex and challenging discovery phase of ADCs,” said Dr Cynthia Wooge, Global Strategic Marketing Manager for SAFC. “ADC Express allows our customers to leverage our platform expertise when they need it most, providing development grade constructs to fit timeline and budget obligations.”
The ADC Express service features access to SAFC‘s platform technology, including:
• Prep scale: 10-200 mg ADC construct +/- column purification
• Certificate of testing with key quality attributes
• ADC concentration
• Payload density DAR (drug antibody ratio)
• Monomer/aggregate content
The delivery results are:
• Rapid production of development grade ADC constructs
• Key analytical characterization
• Cost effective expert assistance for discovery
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance